Market Closed -
NSE India S.E.
07:43:52 2024-05-31 am EDT
5-day change
1st Jan Change
1,840
INR
-0.54%
-2.43%
-4.38%
Sales 2024
56.65B
679M
Sales 2025 *
64B
767M
Capitalization
303B
3.63B
Net income 2024
7.72B
92.62M
Net income 2025 *
9.53B
114M
EV / Sales 2024
5.37
x
Net cash position
2024
*
25.38B
304M
Net cash position
2025
*
18.45B
221M
EV / Sales 2025 *
4.45
x P/E ratio 2024
39.4
x
P/E ratio 2025 *
31.8
x
Employees
4,585
Yield 2024 *
0.13%
Yield 2025 *
-
Free-Float
38.38%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
5 minutes 15 minutes 30 minutes 1 hour 1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
Gland Pharma Limited Announces Resignation of C.S. Venkatesan as Sr. Vice President (R&D) and SMP, Effective June 30, 2024 and July 1, 2024 Respectively
May. 31
CI
Gland Pharma Gets Zero Observations from US FDA for API Facility in Andhra Pradesh, India
May. 24
MT
Jefferies Adjusts Gland Pharma's Price Target to INR2,240 From INR2,400, Keeps at Buy
May. 23
MT
Gland Pharma Posts Surge in Fiscal Q4 Consolidated Net Profit
May. 23
MT
Transcript : Gland Pharma Limited, Q4 2024 Earnings Call, May 22, 2024
May. 22
Gland Pharma Limited Board Recommends Final Dividend for the Fiscal Year Ending March 31, 2024
May. 22
CI
Gland Pharma Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024
May. 22
CI
Gland Pharma Limited Reports Earnings Results for the Full Year Ended March 31, 2024
May. 22
CI
Gland Pharma Gets US FDA's Approval for Generic ALS Drug
May. 07
MT
Gland Pharma Limited Receives Approval from the United States Food and Drug Administration for Edaravone Injection
May. 07
CI
Gland Pharma Gets US FDA's Approval for Generic Stem Cell Mobilizer Injection
May. 07
MT
Gland Pharma Limited Receives Approval from the United States Food and Drug Administration for Plerixafor Injection
May. 07
CI
KKR to buy India's Healthium Medtech at $839 million valuation, sources say
May. 06
RE
Gland Pharma Names COO
Apr. 29
MT
Gland Pharma Limited Approves Appointment of Mr. Satnam Singh Loomba as Chief Operating Officer, Effective May 1 ,2024
Apr. 29
CI
More news
Jefferies Adjusts Gland Pharma's Price Target to INR2,240 From INR2,400, Keeps at Buy
May. 23
MT
Jefferies Adjusts Gland Pharma’s Price Target to INR2,400 From INR2,250, Keeps at Buy
Feb. 15
MT
Indian shares set to open lower as hot US inflation spurs rate worries
Feb. 13
RE
Nomura Upgrades Gland Pharma to Neutral From Reduce, Adjusts Price Target to INR1,570 From INR1,157
Nov. 08
MT
Jefferies Adjusts Gland Pharma's Price Target to INR1,800 From INR1,640, Keeps at Buy
Nov. 07
MT
More recommendations
EN DIRECTO DESDE LOS MERCADOS: Merlin, ASM International, Snap, Nestlé, Microsoft, Apple, Disney, EasyJet...
22-11-29
Bolsa de Madrid: Jay envía a sus Halcones a la caza
22-11-29
Jay envoie ses Faucons en chasse
22-11-29
En Direct des Marchés : Société Générale, Technip Energies, Ipsos, Nestlé, Microsoft, Apple, Disney, EasyJet...
22-11-29
More news 1 day -0.54%
1 week -2.43%
1 month +7.54%
3 months +2.94%
6 months +1.70%
Current year -4.38%
More quotes
Managers
Title Age Since
Chief Executive Officer
55
99-12-31
Director of Finance/CFO
-
19-09-29
Chief Tech/Sci/R&D Officer
-
97-12-31
Members of the board
Title Age Since
Director/Board Member
54
22-03-09
Chief Executive Officer
55
99-12-31
Chairman
69
19-06-09
More insiders
Date
Price
Change
Volume
24-05-31
1,840
-0.54%
192,335
24-05-30
1,850
-0.58%
268,605
24-05-29
1,861
+2.56%
196,219
24-05-28
1,815
-2.77%
151,435
24-05-27
1,866
-1.03%
747,213
Delayed Quote
NSE India S.E., May 31, 2024 at 07:43 am EDT
More quotes
Gland Pharma Limited is an India-based generic injectables manufacturer. The Company specializes in sterile injectables, oncology, and ophthalmic, with a specific focus on complex injectables, NCE-1s (New Chemical Entities), First-to-File products, and 505(b)(2) filings. The Company functions primarily on a business-to-business (B2B) model and has a record in pharmaceutical research and development, manufacturing, and marketing of complex injectables. The Company offers a range of delivery systems, including liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags, and drops. It is also in the process of including new delivery systems such as pens and cartridges into its product portfolio. Its key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. Its therapeutic products categories include Anti Malarials, Anti-Infectives, Anti-Neoplastics, Gynaecological, Hormones, and others.
More about the company
Last Close Price
1,840
INR
Average target price
1,834
INR
Spread / Average Target
-0.31%
Consensus
1st Jan change
Capi.
-4.38% 3.63B +40.73% 739B +32.83% 598B -6.30% 353B +15.15% 318B +4.05% 285B +15.00% 240B -5.52% 206B +6.17% 164B -0.45% 162B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1